Obinutuzumab (GA101) – a different anti-CD20 antibody with great expectations

The future of anti-CD20 monoclonal antibodies: are we making progress?

(2011) W. Alduaij et al.   BLOOD

Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies

(2011) W. Alduaij et al.   BLOOD

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

(2010) E. Mossner et al.   BLOOD

Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection

(2010) S. A. Beers et al.   BLOOD

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

(2010) M Hallek et al.   LANCET

Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance

(2009) J. Hiraga et al.   BLOOD